is lower in apoE4 transgenic mice compared with apoE3 mice, indicating impaired synaptogen-esis (12, 13). ApoE4 is less efficient than apoE3 in transporting brain cholesterol (14) and is also less e fective …
Synaptogenix | Neurotrope Appoints Charles S. Ramat and Paul …
Plantation, FL. – June 19, 2014 – Neurotrope, Inc. (OTCQB: NTRP) has appointed Messrs. Charles S. Ramat and Paul Freiman as Co-Chairmen of its Board of Directors. Mr. Freiman previously served …
Morgantown, WV 26505 Running title: Rescuing synapses and spatial memory in young fragile X mice
Neurotrope Launches New Long-Term Clinical Trial of ... - Synaptogen
NEW YORK, May 28, 2020 – Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer’s disease (AD). The …
Synaptogenix | Neurotrope’s President and Chief Scientific Officer to ...
NEW YORK, March 24, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including …
Neurotrope Announces Cooperative Research and Development
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute
Dec 5, 2014 · Apolipoprotein E (ApoE) is a critical signal for synaptogen-esis and synaptic maturation [101]. ApoE/cholesterol com-plex released from astrocytes is taken up through low-density …
Traumatic brain injury (TBI) is a frequent consequence of vehicle, sport and war related injuries. More than 90% of TBI patients suffer mild injury (mTBI). However, the pathologies underlying the disease …
Synaptogenix | Neurotrope Appoints Neuroscientist Sam Kongsamut as ...
Plantation, FL. – June 4, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today the appointment of Sam Kongsamut, Ph.D., as Executive Director, Pharmacology, effective immediately. In this role, Dr. …
Martin R. Farlow, MD Accera, AstraZeneca, Avanir, Axovant, AZTherapies, Biogen, Boehringer Ingelheim, Chase Pharmaceuticals, Eisai, Eli Lilly & Company, FORUM ...